CAPEOX/XELOX

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, First Affiliated Hospital of Zhejiang University, Sun Yat-sen University

Conditions

Colorectal CancerColorectal Cancer (CRC)Colorectal CarcinomaMSSOligometastasesiTNTpMMR

Phase 2

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

CompletedNCT00551213

Merck Sharp & Dohme LLCColorectal Cancer

Start: 2007-11-21End: 2009-06-04Updated: 2018-08-24

SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases

RecruitingNCT06850103

First Affiliated Hospital of Zhejiang UniversityColorectal Carcinoma, iTNT, MSS +2

Start: 2025-04-22End: 2032-12-01Target: 51Updated: 2026-03-25

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

RecruitingNCT07448142

Sun Yat-sen UniversityColorectal Cancer (CRC)

Start: 2026-03-15End: 2032-09-01Target: 50Updated: 2026-03-04